Intravitreal cord-blood platelet-rich plasma for dry-AMD: Safety profile

Abstract

This report was prepared to promote the safety results of intravitreal cord-blood platelet-rich plasma (CB-PRP) use for dry-age-related macular degeneration (dry-AMD) as possible regenerative therapy. We believe that the safety data is important to convey while waiting for the results of possible efficacy. A dissemination of safety information in the use of CB-PRP for intravitreal use could help us with future collaborations and be able to study its real potential that only large numbers can provide. We believe in the regenerative power of CB-PRP. Moreover, funding for this research is completely absent. We trust that the Editor may consider it.